Evidence map›Paper›PMID 36354709›Full record

ArticleCurrent oncology (Toronto, Ont.)2022

Efficacy and Feasibility of Proton Beam Therapy in Relapsed High-Risk Neuroblastoma-Experiences from the Prospective KiProReg Registry.

Danny Jazmati, Barbara Hero, Theresa M Thole-Kliesch, Julien Merta, Hedwig E Deubzer, Christian Bäumer, Feline Heinzelmann, Stefanie Schulze Schleithoff, Friederike Koerber, Angelika Eggert and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Current oncology (Toronto, Ont.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 1 country.

Danny JazmatiDepartment of Particle Therapy, University Hospital Essen, West German Proton Therapy Centre Essen (WPE), West German Cancer Center (WTZ), 45147 Essen, Germany.
Barbara HeroChildren's Hospital, University of Cologne, 50937 Cologne, Germany.
Theresa M Thole-KlieschDepartment of Pediatric Oncology/Hematology, Charité-Universitätsmedizin 10117 Berlin, Germany.
Julien MertaDepartment of Particle Therapy, University Hospital Essen, West German Proton Therapy Centre Essen (WPE), West German Cancer Center (WTZ), 45147 Essen, Germany.
Hedwig E DeubzerDepartment of Pediatric Oncology/Hematology, Charité-Universitätsmedizin 10117 Berlin, Germany.ORCID 0000-0002-6115-4893
Christian BäumerWest German Proton Therapy Centre Essen (WPE), West German Cancer Center (WTZ), 45147 Essen, Germany.ORCID 0000-0003-0512-1146
Feline HeinzelmannWest German Proton Therapy Centre Essen (WPE), West German Cancer Center (WTZ), 45147 Essen, Germany.
Stefanie Schulze SchleithoffDepartment of Particle Therapy, University Hospital Essen, West German Proton Therapy Centre Essen (WPE), West German Cancer Center (WTZ), 45147 Essen, Germany.
Friederike KoerberDepartment of Radiology, University of Cologne, 50937 Cologne, Germany.
Angelika EggertDepartment of Pediatric Oncology/Hematology, Charité-Universitätsmedizin 10117 Berlin, Germany.ORCID 0000-0003-3476-8184
Rudolf SchwarzDepartment of RT and Radiooncology, Outpatient Center, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246 Hamburg, Germany.
Thorsten SimonChildren's Hospital, University of Cologne, 50937 Cologne, Germany.ORCID 0000-0002-3425-8451
Beate TimmermannDepartment of Particle Therapy, University Hospital Essen, West German Proton Therapy Centre Essen (WPE), West German Cancer Center (WTZ), 45147 Essen, Germany.
West German Heart and Vascular Center Essen · DECharité - Universitätsmedizin Berlin · DEUniversity of Cologne · DETU Dortmund University · DEUniversität Hamburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDespite an intensive multimodal treatment approach, approximately 50% of high-risk (HR) neuroblastoma (NB) patients experience progression. Despite the advances in targeted therapy, high-dose chemotherapy, and other systemic treatment options, radiation therapy (RT) to sites of relapsed disease can be an option to reduce tumor burden and improve chance for disease control.

methodsPatients who received salvage irradiation with proton beam therapy (PBT) for local or metastatic relapse of HR NB within the prospective registry trials KiProReg and ProReg were eligible for this retrospective analysis. Data on patient characteristics, multimodality therapy, adverse events, and oncologic endpoints were evaluated. Adverse events were assessed before, during, and after PBT according to common terminology criteria for adverse events (CTCAE) V4.0.

resultsBetween September 2013 and September 2020, twenty (11 male; 9 female) consecutive patients experiencing local (

conclusionOur study demonstrates the efficacy and safety of RT/PBT for recurrent HR NB in a multimodality second-line approach. To better define the role of RT for these patients, prospective studies would be desirable.

Indexed as

NeuroblastomaProton TherapyFeasibility StudiesFemaleHumansMaleNeoplasm Recurrence, LocalProspective StudiesRegistriesRetrospective Studieschildhood cancerNeuroblastomaproton beam therapy

Identifiers

PMID36354709
PMCPMC9689739
OpenAlexW4307943780

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.